Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 10/20 | 0.45 |
| ▸ | RAB9A | P51151 | 7/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | GLA | P06280 | 3/20 | 0.40 |
| ▸ | RUNX1 | Q01196 | 3/20 | 0.40 |
| ▸ | CBFB | Q13951 | 3/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23862103 | 0.83 | POLB (0.53) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22488059 | 0.83 | POLB (0.53) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1665445 | 0.81 | PDK1 (0.53) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20312936 | 0.80 | POLB (0.50) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23843281 | 0.79 | PDK1 (0.39) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL20312949 | 0.78 | NPC1 (0.53) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22487970 | 0.75 | NPC1 (0.50) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL29390917 | 0.75 | PDK1 (0.58) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2176039 | 0.75 | PDK1 (0.58) | PDK1POLBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1002931 | 0.74 | PDK1 (0.73) | PDK1POLBNPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271969-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-20230271969-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-08-31 | — | — | US | disclosed |
| US-11712480-B2 | Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates | PFIZER INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230234951-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2023-07-27 | — | — | US | disclosed |
| US-20220017510-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2022-01-20 | — | — | US | disclosed |
| EP-3317273-B1 | INHIBITORS OF EGFR AND METHODS OF USE THEREOF | DANA FARBER CANCER INST INC (US) | 2021-12-29 | — | — | EP | disclosed |
| US-11161842-B2 | Bifunctional molecules for degradation of EGFR and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-11129814-B2 | Antimicrobial agents | TAXIS PHARMACEUTICALS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| EP-3445357-B1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | DANA FARBER CANCER INST INC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-10995090-B2 | Substituted dihydrobenzofuran glycosidase inhibitors | ASCENEURON SA (CH) | 2021-05-04 | — | — | US | disclosed |
| US-20100298388-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD. (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | ACHAOGEN, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | BRISTOL-MYERS SQUIBB COMPANY | 2010-04-22 | — | — | US | disclosed |
| US-20090325953-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-29 | — | — | US | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090156594-A1 | HETEROCYCLIC KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2009-06-18 | — | — | US | disclosed |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099684-A1 | Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands | CHRNA7, CHRNA5, CHRNA6 | PDK1 3352/4885POLB 2083/4885NPC1 896/4885 |
| US-20220017510-A1 | BIFUNCTIONAL MOLECULES FOR DEGRADATION OF EGFR AND METHODS OF USE | EGFR, ERBB2, ERBB3 | PDK1 3087/4885POLB 2404/4885NPC1 3629/4885 |
| US-11129814-B2 | Antimicrobial agents | MRPL21, SPOUT1, LSS | PDK1 3959/4885POLB 186/4885NPC1 761/4885 |
| US-20100267686-A1 | CARBACEPHEM BETA-LACTAM ANTIBIOTICS | MGAM, MGAM2, B2M | PDK1 3234/4885POLB 2510/4885NPC1 1818/4885 |
| US-20090270405-A1 | QUINUCLIDINE COMPOUNDS AS ALPHA-7 NICOTINIC ACETYLCHOLINE RECEPTOR LIGANDS | CHRNA7, CHRNA5, CHRNA6 | PDK1 3352/4885POLB 2083/4885NPC1 896/4885 |
| US-20090325953-A1 | P38 KINASE INHIBITING AGENTS | MAPK1, MAPK8, MAPKAPK2 | PDK1 636/4885POLB 1822/4885NPC1 4023/4885 |
| US-11161842-B2 | Bifunctional molecules for degradation of EGFR and methods of use | EGFR, ERBB2, ERBB3 | PDK1 3087/4885POLB 2404/4885NPC1 3629/4885 |
| US-20230234951-A1 | CYCLOPROPYL-(HETERO)ARYL-SUBSTITUTED ETHYLSULPHONYL-PYRIDINE DERIVATIVES | CYCS, CYP2E1, AHR | PDK1 2175/4885POLB 3988/4885NPC1 2128/4885 |
| US-20090156603-A1 | 2-AMINOPYRIDINE ANALOGS AS GLUCOKINASE ACTIVATORS | GCK, GCKR, PRKCSH | PDK1 92/4885POLB 442/4885NPC1 4280/4885 |
| US-20230271969-A1 | NITROGEN-CONTAINING FUSED RING DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | NR5A1, WEE1, SHBG | PDK1 177/4885POLB 3238/4885NPC1 643/4885 |
| US-20100298388-A1 | SUBSTITUTED BENAMIDINES AS ANTIBACTERIAL AGENTS | ALK, CBR3, CBR1 | PDK1 3572/4885POLB 1175/4885NPC1 2023/4885 |
| US-20090156594-A1 | HETEROCYCLIC KINASE MODULATORS | MAP3K20, MAP4K2, MAP3K13 | PDK1 304/4885POLB 2559/4885NPC1 3227/4885 |
| US-11712480-B2 | Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates | SULT1E1, SULT2A1, STS | PDK1 4406/4885POLB 3982/4885NPC1 2752/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | PDK1 4131/4885POLB 364/4885NPC1 1400/4885 |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | MAP3K20, TTK, PRKACB | PDK1 412/4885POLB 2724/4885NPC1 2325/4885 |
| US-10995090-B2 | Substituted dihydrobenzofuran glycosidase inhibitors | GAA, ENGASE, BACE1 | PDK1 2313/4885POLB 1787/4885NPC1 678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.